# Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00109824** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Mantle Cell Lymphoma

## Interventions

- **DRUG:** decitabine
- **DRUG:** valproic acid
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00109824
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2009-03
- **Final completion:** —
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109824, "Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00109824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*